Qinglong Wu

Qinglong Wu

Auto-generated profile, based on publicly available information

Qinglong Wu

Department of Pathology and Immunology Baylor College of Medicine Houston Texas USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2022 in Nature Methods
Verified
Journal Article
Closed access
PDF file
KCKristen D. Curry
Kristen D. Curry
QWQi Wang
Qi Wang
MNMichael G. Nute
Michael G. Nute
ATAlona Tyshaieva
Alona Tyshaieva
ERElizabeth Reeves
Elizabeth Reeves
TTTodd J Treangen
Todd J Treangen

11 February 2021 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
HWHua Wei
Hua Wei
QYQin Yang
Qin Yang
XMXuan Mi
Xuan Mi
LQLiang Qiu
Liang Qiu
XTXueying Tao
Xueying Tao
HWHua Wei
Hua Wei

1 January 2015 in Trends in Food Science & Technology
Verified
Journal Article
Closed access
QWQinglong Wu
Qinglong Wu
CCChristine K.W. Cheung
Christine K.W. Cheung
NSNagendra P. Shah
Nagendra P. Shah

26 February 2021 in Critical Reviews in Food Science and Nutrition
Verified
Journal Article
Closed access
YHYina Huang
Yina Huang
KXKeyu Xing
Keyu Xing
LQLiang Qiu
Liang Qiu
QWQinglong Wu
Qinglong Wu
HWHua Wei
Hua Wei
Inflammatory bowel disease (IBD) is a chronic gastro-intestinal disorders of unknown etiology. There are several drugs approved for treating IBD patients with active disease, including first-line use of aminosalicylates, and secondary choices of immunomodulators and other therapies. These medications might manage disease symptoms, but have also shown significant side-effects in IBD patients. Tea is the second largest beverage in the world and its main active ingredients including tea polyphenols, polysaccharides and tea pigments have been shown promising anti-inflammatory and antioxidant properties. In this review, we summarize the influence of different tea varieties including green tea, black tea and dark tea as potential nutritional therapy for preventing and treating IBD, and discuss the mechanisms of tea ingredients involved in the regulation of oxidative stress, inflammation, signaling pathways, and gut microbiota that could benefit for IBD disease management. Our observation directs further basic and clinical investigations on tea polyphenols and their derivatives as novel IBD therapeutic agents.

2 April 2020 in Food & Function
Verified
Journal Article
Closed access
PDF file
YHYina Huang
Yina Huang
LQLiang Qiu
Liang Qiu
XMXuan Mi
Xuan Mi
ZZZhihong Zhang
Zhihong Zhang
DXDi Xu
Di Xu
HWHua Wei
Hua Wei
Tea consumption has been found to be associated with low incidence of inflammatory bowel disease in Asian countries. However, there is very limited knowledge of such potential protection and its underlying mechanism. Ripened Pu-erh tea (RPT) belongs to the variety of microbial fermented tea, but its function regarding anti-inflammation remains unclear. In the present study, we investigated the effects of RPT on dextran sulfate sodium (DSS)-induced colitis in mice. The results demonstrated that RPT significantly relieved the loss of body weight, disease severity and shortening of colon length, and remarkably inhibited the secretion of pro-inflammatory cytokines by lessening the infiltration of inflammatory cells. Furthermore, we found that RPT suppressed the activation of the NF-κB pathway and down-regulated the expression of HIF-1α. Thus, it was concluded that RPT attenuated the progress of colitis via suppressing the HIF-1α/NF-κB signaling pathways thus reducing inflammation. This suggests that RPT may be a potential anti-inflammatory nutraceutical for the prevention and treatment of colonic colitis.

31 January 2024 in iMeta
Verified
Journal Article
Open access
XXXinming Xu
Xinming Xu
QFQingying Feng
Qingying Feng
TZTao Zhang
Tao Zhang
YGYunlong Gao
Yunlong Gao
QCQu Cheng
Qu Cheng
JLJinxin Liu
Jinxin Liu
The infant gut microbiome is increasingly recognized as a reservoir of antibiotic resistance genes, yet the assembly of gut resistome in infants and its influencing factors remain largely unknown. We characterized resistome in 4132 metagenomes from 963 infants in six countries and 4285 resistance genes were observed. The inherent resistome pattern of healthy infants (N = 272) could be distinguished by two stages: a multicompound resistance phase (Months 0–7) and a tetracycline‐mupirocin‐β‐lactam‐dominant phase (Months 8–14). Microbial taxonomy explained 40.7% of the gut resistome of healthy infants, with Escherichia (25.5%) harboring the most resistance genes. In a further analysis with all available infants (N = 963), we found age was the strongest influencer on the resistome and was negatively correlated with the overall resistance during the first 3 years (p < 0.001). Using a random‐forest approach, a set of 34 resistance genes could be used to predict age (R2 = 68.0%). Leveraging microbial host inference analyses, we inferred the age‐dependent assembly of infant resistome was a result of shifts in the gut microbiome, primarily driven by changes in taxa that disproportionately harbor resistance genes across taxa (e.g., Escherichia coli more frequently harbored resistance genes than other taxa). We performed metagenomic functional profiling and metagenomic assembled genome analyses whose results indicate that the development of gut resistome was driven by changes in microbial carbohydrate metabolism, with an increasing need for carbohydrate‐active enzymes from Bacteroidota and a decreasing need for Pseudomonadota during infancy. Importantly, we observed increased acquired resistance genes over time, which was related to increased horizontal gene transfer in the developing infant gut microbiome. In summary, infant age was negatively correlated with antimicrobial resistance gene levels, reflecting a composition shift in the gut microbiome, likely driven by the changing need for microbial carbohydrate metabolism during early life.